ShahAG, LydeckerA, MurrayK, TetriBN, ContosMJ, SanyalAJ.Use of the FIB4 index for non-invasive evaluation of fibrosis in nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol. 2009;7(10):1104–1112. doi:10.1016/j.cgh.2009.05.033
3.
KimRG, DengJ, ReasoJN, GrenertJP, KhaliliM.Noninvasive fibrosis screening in fatty liver disease among vulnerable populations: impact of diabetes and obesity on FIB-4 score accuracy. Diabetes Care. 2022;45(10):2449–2451. doi:10.2337/dc22-0556
4.
Food and Drug Administration. FDA approves treatment for serious liver disease known as ‘MASH’. Published August 15, 2025. Accessed August 19, 2025. https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
